Company Overview - Edwards Lifesciences Corporation (EW) is valued at a market cap of $47.4 billion and is based in Irvine, California, focusing on products and technologies for advanced cardiovascular diseases [1] - EW is classified as a "large-cap stock" due to its market cap exceeding $10 billion, highlighting its size and influence in the medical devices industry [2] Recent Developments - The company recently divested its critical care unit to concentrate on high-growth areas such as asymptomatic aortic stenosis and structural heart failure [2] - EW's Q4 results showed a 13.3% year-over-year increase in net sales to $1.6 billion, although adjusted EPS declined by 1.7% to $0.58 [7] Stock Performance - EW shares have decreased by 6.6% from their 52-week high of $87.89, reached on December 5, 2025, and have declined 1.8% over the past three months, outperforming the S&P 500 Index's 2.4% drop [3] - Over the past 52 weeks, EW has increased by 16.3%, surpassing the S&P 500's 15.7% gain, but is down 4.1% year-to-date, lagging behind the S&P 500's 2.5% loss [6] Competitive Position - EW has outperformed its competitor, Medtronic plc (MDT), which has seen a 4.2% decline over the past 52 weeks and a 5.7% drop year-to-date [8] - Analysts maintain a moderately optimistic outlook for EW, with a consensus rating of "Moderate Buy" and a mean price target of $96.07, indicating a 15.9% premium to current price levels [8]